A US federal court yesterday invalidated Pfizer Inc.’s (NYSE:PFE) key patent covering its anti-inflammatory pill Celebrex. The patent, which was set to lapse in December 2015, would have given Pfizer an 18-month extension from the expiry of the patent for the major ingredient in the drug, celecoxib. Pfizer Inc. (NYSE:PFE) stock performance was -2.69% in last session and finished the day at $31.12. Traded volume was 45.90 million shares in the last session and the average volume of the stock remained 27.32 million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.
Levi & Korsinsky commenced an investigation into Geron Corporation (NASDAQ:GERN) for possible breaches of fiduciary duty. Geron Corporation (NASDAQ:GERN) rose 5.62% to $1.78 yesterday on volume of 16.41 million shares. The intra-day range of the stock was $1.69 – $1.95. Geron Corporation (NASDAQ:GERN) has a market capitalization of 229.00 million.
Cell Therapeutics Inc. (NASDAQ:CTIC) jumped 8.18% after the news that U.K. health-cost regulator NICE has given a final recommendation for the use of Cell Therapeutics’ (CTIC) Pixuvri for treating advanced B-cell non-Hodgkin lymphoma. Cell Therapeutics Inc. (NASDAQ:CTIC)’s stock on March 13, 2014 reported a lower of -3.90% to the closing price of $3.94. Its fifty two weeks range is $0.97 – $4.25. The total market capitalization recorded 437.32 million. The overall volume in the last trading session was 13.29 million shares. In its share capital, Cell Therapeutics Inc. (NASDAQ:CTIC) has 111.00 million outstanding shares.
The upward movement of the stock was probably driven by the opinion of analysts at Wedbush that a partnership or acquisition of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) was given approval for Northera by the Food and Drug Administration. On Thursday, shares of Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) advanced 13.98% to close the day at $5.95. Company return on investment (ROI) is – and its monthly performance is recorded as 14.64%. Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) quarterly revenue growth is 64.36%.